Search Results for “Ocrelizumab” – Endpoints News

SIGN UP

search results for: Ocrelizumab

TG crosses the finish line in MS, turning U2 component into standalone drug for biotech's second approval

Last year

TG's MS hopeful ublituximab not cost-effective at Ocrevus' price, ICER says in evidence report

Last year

ICER on MS drugs: TG's ublituximab not cost effective at the same price as Roche's ocrelizumab

Last year

Sanofi's R&D group spotlights a big win for BTKi multiple sclerosis drug. But plenty of questions remain

5 years ago

J&J's head-to-head PhIII data promise drug launch into crowded MS market

5 years ago

ICER goes after Novartis for overpricing MS drug; Valneva, GlaxoSmithKline breaks vaccine pact

5 years ago

Gilead says only Teva can market Truvada generic; Denver narrowly votes to decriminalize "magic mushrooms"

5 years ago

NHS refuses to cover Ocrevus for primary progressive MS; OxStem taps veteran drug hunter Georg Terstappen as CSO

6 years ago

Sanofi loses its German CSO and diabetes chief to Grünenthal; Roche touts longterm advantages of Ocrevus in treating ...

7 years ago

Poised for an FDA pitch, Novartis lays out all its PhIII cards on MS drug siponimod

7 years ago

The class of 2017's winners and losers: A year of 'nonstop scientific achievements' raises troubling issues

7 years ago

Roche gets EMA recommendation for Ocrevus; Anthem now covers Sarepta's exon-skipping Duchenne MD drug

7 years ago

That turnaround on new FDA drug approvals? We’re right on schedule

8 years ago

Megablockbuster day for Roche too as MS game-changer Ocrevus gets a green light at the FDA

8 years ago

Roche will have to wait on its big MS drug application; Pfizer ties up with BioInvent on new antibodies for cancer

8 years ago

Roche adjusts Avastin franchise defense plans as PhII successor fails a key study

8 years ago

GSK makes a little history while outlining a familiar future

8 years ago

Novartis shows a hole card in a high-stakes PhIII poker game for MS drugs

8 years ago

12 Next page Last page

latest

Most read

GSK accuses Pfizer and BioNTech of mRNA patent infringement

9 hours ago

Gilead leans on CymaBay liver drug, Trodelvy readouts and long-active PrEP yet to come this year

5 hours ago

In rare move, Colombia issues compulsory license for HIV medicine in effort to expand access

8 hours ago

Esteve to acquire Perrigo's rare disease pharma business for up to $295M

9 hours ago

FDA revises guidance on biosimilar promotional labels and advertising

9 hours ago

see latest stream